1. Home
  2. TEVA
  3. TEVA News

Latest Teva Pharmaceutical Industries Limited (TEVA) News on December 22, 2024

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
TEVA

Insider Monkey

17 hours ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
TEVA

GlobeNewswire

a day ago

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
TEVA

Zacks

2 days ago

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

My Top 10 Portfolio Holdings for 2025
TEVA

Motley Fool

2 days ago

My Top 10 Portfolio Holdings for 2025

Teva price target raised to $28 from $26 at UBS
TEVA

TipRanks

3 days ago

Teva price target raised to $28 from $26 at UBS

Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
TEVA

Insider Monkey

3 days ago

Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?

TEVA

MT Newswires

4 days ago

Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says

TEVA

MT Newswires

4 days ago

BofA Securities Raises Price Target on Teva Pharmaceutical Industries to $25 From $23, Keeps Buy Rating

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
TEVA

Zacks

4 days ago

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Fed decision looms, Nvidia looks to rebound: Yahoo Finance
TEVA

Yahoo Finance Video

4 days ago

Fed decision looms, Nvidia looks to rebound: Yahoo Finance

Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
TEVA

Zacks

4 days ago

Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
TEVA

Clinical Trials Arena

4 days ago

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial

TEVA

Morningstar Research

4 days ago

Analyst Report: Teva Pharmaceutical Industries Limited

Teva and Sanofi jump on experimental bowel disease drug success
TEVA

Yahoo Finance Video

4 days ago

Teva and Sanofi jump on experimental bowel disease drug success

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
TEVA

Investor's Business Daily

4 days ago

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
TEVA

MT Newswires

4 days ago

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
TEVA

Investopedia

4 days ago

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

TEVA

MT Newswires

5 days ago

Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations
TEVA

GuruFocus.com

5 days ago

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

Teva, Cloudflare, Sanofi: Trending Tickers
TEVA

Yahoo Finance Video

5 days ago

Teva, Cloudflare, Sanofi: Trending Tickers

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
TEVA

The Wall Street Journal

5 days ago

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
TEVA

Investor's Business Daily

5 days ago

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva Shares Soar on Early Bowel Disease Drug Data
TEVA

Barrons.com

5 days ago

Teva Shares Soar on Early Bowel Disease Drug Data

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
TEVA

Benzinga

5 days ago

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

TEVA

MT Newswires

5 days ago

Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
TEVA

GlobeNewswire

5 days ago

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
TEVA

GlobeNewswire

11 days ago

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

TEVA

MT Newswires

16 days ago

Teva Pharmaceutical to Divest Japanese Venture to JKI

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
TEVA

GlobeNewswire

16 days ago

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva reports positive outcomes from episodic migraine trial in young patients
TEVA

Clinical Trials Arena

17 days ago

Teva reports positive outcomes from episodic migraine trial in young patients

TEVA

MT Newswires

18 days ago

Teva Pharmaceutical Says Migraine Prevention Drug Shows Efficacy in Younger Patients

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
TEVA

GlobeNewswire

18 days ago

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

TEVA Stock Down 10% in a Month: Should You Buy the Dip?
TEVA

Zacks

23 days ago

TEVA Stock Down 10% in a Month: Should You Buy the Dip?

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
TEVA

GlobeNewswire

a month ago

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
TEVA

Insider Monkey

a month ago

Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25

TEVA

Argus Research

a month ago

Weekly Stock List

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
TEVA

Insider Monkey

a month ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

TEVA

Argus Research

a month ago

Analyst Report: Teva Phar Inds Lt

TEVA

Argus Research

a month ago

Market Update: CP, TEVA, MET, IGT

Teva to Present at the Jefferies London Healthcare Conference
TEVA

GlobeNewswire

a month ago

Teva to Present at the Jefferies London Healthcare Conference

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
TEVA

Zacks

a month ago

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
TEVA

Zacks

a month ago

Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
TEVA

Zacks

a month ago

TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...
TEVA

GuruFocus.com

a month ago

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...

'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe.
TEVA

Investor's Business Daily

a month ago

'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe.

TEVA

Morningstar Research

a month ago

Analyst Report: Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
TEVA

Motley Fool

2 months ago

Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript

Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
TEVA

GuruFocus.com

2 months ago

Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge

Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
TEVA

Zacks

2 months ago

Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say

Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
TEVA

Investor's Business Daily

2 months ago

Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report

TEVA

MT Newswires

2 months ago

Teva Pharmaceutical Q3 Non-GAAP Earnings, Net Revenue Rise; 2024 Outlook Updated

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
TEVA

GlobeNewswire

2 months ago

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
TEVA

Zacks

2 months ago

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
TEVA

Zacks

2 months ago

Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?

TEVA

MT Newswires

2 months ago

Teva Pharmaceuticals Schizophrenia Drug Delivery Trial Shows Improvement in Social Functioning

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
TEVA

GlobeNewswire

2 months ago

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
TEVA

GlobeNewswire

2 months ago

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
TEVA

Zacks

2 months ago

Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
TEVA

Pharmaceutical Technology

2 months ago

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

TEVA

Morningstar Research

2 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
TEVA

Associated Press Finance

2 months ago

EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug

TEVA

MT Newswires

2 months ago

Update: European Commission Fines Teva $502.8 Million

TEVA

MT Newswires

2 months ago

European Commission Fines Teva $502.8 Million

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
TEVA

The Wall Street Journal

2 months ago

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns

Teva Statement on European Commission Decision; Company to Appeal
TEVA

GlobeNewswire

2 months ago

Teva Statement on European Commission Decision; Company to Appeal

Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year
TEVA

Simply Wall St.

2 months ago

Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year

Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know
TEVA

Zacks

2 months ago

Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
TEVA

Zacks

2 months ago

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
TEVA

Zacks

2 months ago

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
TEVA

Zacks

2 months ago

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
TEVA

Insider Monkey

2 months ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

TEVA

MT Newswires

2 months ago

Alvotech, Teva's Stelara Biosimilar Gets FDA Approval for New IV Presentation

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
TEVA

GlobeNewswire

2 months ago

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
TEVA

Zacks

2 months ago

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
TEVA

Zacks

2 months ago

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?

TEVA

MT Newswires

2 months ago

Update: Amicus Therapeutics Shares Surge After Settling Patent Suit Against Teva Pharmaceuticals With License Deal

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
TEVA

Benzinga

2 months ago

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

TEVA

MT Newswires

2 months ago

Amicus Therapeutics Settles Patent Suit Against Teva Pharmaceuticals with License Agreement

TEVA

MT Newswires

2 months ago

Sector Update: Health Care Stocks Higher Friday Afternoon

TEVA

MT Newswires

2 months ago

Sector Update: Health Care

Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
TEVA

Benzinga

2 months ago

Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes

TEVA

MT Newswires

2 months ago

Update: Teva Pharmaceutical to Pay $450 Million to Settle Anti-Kickback Allegations

TEVA

MT Newswires

2 months ago

Teva Pharmaceutical to Pay $450 Million to Settle Anti-Kickback Allegations

Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations
TEVA

The Wall Street Journal

2 months ago

Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...
TEVA

GuruFocus.com

2 months ago

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...

TEVA

MT Newswires

2 months ago

Teva Pharmaceutical Says it Receives FDA, EMA Acceptance for Prolia Biosimilar Candidate Applications

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
TEVA

GlobeNewswire

2 months ago

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
TEVA

Zacks

2 months ago

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
TEVA

Zacks

2 months ago

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?

Teva and mAbxience partner to develop biosimilar candidate for oncology
TEVA

Pharmaceutical Technology

3 months ago

Teva and mAbxience partner to develop biosimilar candidate for oncology

TEVA

MT Newswires

3 months ago

Teva Unit, mAbxience Partner to Develop Anti-PD-1 Oncology Biosimilar

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
TEVA

GlobeNewswire

3 months ago

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

TEVA

MT Newswires

3 months ago

Teva Pharmaceutical's US Affiliate Launches Octreotide Acetate for Injectable Suspension

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
TEVA

GlobeNewswire

3 months ago

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
TEVA

Insider Monkey

3 months ago

Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
TEVA

GlobeNewswire

3 months ago

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...
TEVA

GuruFocus.com

3 months ago

Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...

Teva touts safety profile of once monthly schizophrenia therapy
TEVA

Pharmaceutical Technology

3 months ago

Teva touts safety profile of once monthly schizophrenia therapy

Teva touts safety profile of once-monthly schizophrenia therapy
TEVA

Clinical Trials Arena

3 months ago

Teva touts safety profile of once-monthly schizophrenia therapy

TEVA

MT Newswires

3 months ago

Teva Pharmaceutical's Movement Disorder Drug Shows Sustained Improvement in Extension Study

Share on Social Networks: